Boehringer Ingelheim

The firm manages around $500M. That capital backs Boehringer Ingelheim's thesis across AI companies — from early-stage rounds through growth-stage follow-ons.

Boehringer Ingelheim concentrates on AI, Pharma, Biotech. That focus has shaped a portfolio of companies building at the intersection of these areas.

Boehringer Ingelheim has backed at least 2 AI companies that Awaira tracks. Venture portfolios often include undisclosed bets, so the true count could be larger.

Most of Boehringer Ingelheim's capital goes into Late Stage rounds. This stage preference aligns with their fund structure and return expectations.

Among Boehringer Ingelheim's portfolio, the standout deal is Boehringer Ingelheim is a growth-stage investment firm founded in 1885, headquartered in Germany, managing approximately $500M in assets under management. The firm concentrates on AI, Pharma, Biotech, deploying capital primarily at the late stage level. Notable AI portfolio companies include Aleph Alpha, Insitro. Boehringer Ingelheim has participated in 2 funding rounds tracked by Awaira, deploying capital across AI, Pharma, Biotech sectors. The firm's investment strategy emphasizes AI applications in healthcare and life sciences. Awaira assigns Boehringer Ingelheim an investor score of 58/100 based on portfolio strength, AI sector exposure, and market activity. The firm investment thesis centers on identifying AI companies that demonstrate strong technical moats, clear paths to revenue, and potential for category leadership within their respective segments. Boehringer Ingelheim evaluates opportunities based on team quality, market timing, technology differentiation, and capital efficiency. Portfolio companies including Aleph Alpha, Insitro reflect the firm emphasis on backing founders who combine deep technical expertise with commercial execution capability.. This investment reflects the firm's broader strategy and risk appetite in the AI market.